To achieve this goal, it will be necessary to increase the number and clinical stages of EOC samples to analyze the expression level of PHF20L1; furthermore, correlation analyses with the expression of additional markers, such as CA125 or Ki67, in tumor tissues should be performed given that these molecules may indicate recurrence or response to therapy (CA125) or a high rate of cell proliferation (Ki67). Here, PHF20L1 is linked to neoplasm.